How much revenue does Hunan Jingfeng Pharmaceutical make?

Hunan Jingfeng Pharmaceutical reported 378.11 million CNY in revenue for fiscal year 2025, down 9.1% from 416.03 million CNY in fiscal year 2024. In Q1 2026 revenue was 107.54 million CNY.

What is Hunan Jingfeng Pharmaceutical's largest business segment?

Pharmaceuticals, with 391.27 million CNY or 94% of segment revenue in fiscal year 2024. Next: Others (6%).

Where does Hunan Jingfeng Pharmaceutical make most of its revenue?

East China: 35% of revenue by region in fiscal year 2024, followed by North China (25%).

What companies are similar to Hunan Jingfeng Pharmaceutical?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Yifan Pharmaceutical Co., Ltd. (002019.SZ), Shanghai Haixin Group Co., Ltd. (600851.SS), Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS), Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ).

Hunan Jingfeng Pharmaceutical Co.,Ltd. (000908.SZ) Stock

About Hunan Jingfeng Pharmaceutical Co.,Ltd.

CSPC Hunan Jingfeng Pharmaceutical Co., Ltd. manufactures and sells chemical drugs and biological agents in China. The company offers sodium hyaluronate injection for use in orthopedics and surgery applications. It also offers ophthalmic devices and API products, as well as engages in the research and development of antitumor, cancer, and cardiovascular drugs; and distributed in the fields of card...

At a glance

Hunan Jingfeng Pharmaceutical reported revenue of 378.11 million CNY for fiscal year 2025, down 9.1% from fiscal year 2024, and net income of -80.89 million CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 107.54 million CNY, up 7.4% from a year before. Its largest business segment, Pharmaceuticals, brought in 94% of segment revenue in fiscal year 2024; East China was the largest region with 35%.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.